Sorafenib for the treatment of renal cancer

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 3, 2012, Pages 407-419

  Strumberg, Dirk ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Combination treatment; Renal cell cancer; Sequential treatment; Sorafenib

Indexed keywords

AG 386; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CREATININE; EVEROLIMUS; INTERLEUKIN 2; PAZOPANIB; RECOMBINANT ALPHA2A INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CANCER PATIENT; CONSTIPATION; CREATININE BLOOD LEVEL; CROSS RESISTANCE; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HAND FOOT SYNDROME; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INFECTION; KIDNEY CARCINOMA; LOW DRUG DOSE; NAUSEA; NEPHROTOXICITY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856243961     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.654776     Document Type: Article

References (67)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
2. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-90 (Pubitemid 41770167)
3. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-17 (Pubitemid 30060482)
4. Coppin C, Porszolt F, Autenrieth M, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;CD001425
5. Bordin V, Giani L, Meregalli S, et al. Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients. Urol Int 2000;64:3-8 (Pubitemid 30224033)
6. Atzpodien J, Reitz M. Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2. Cancer Biother Radiopharm 2005;20:410-16 (Pubitemid 41216105)
7. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40 (Pubitemid 29368255)
8. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96 (Pubitemid 34032623)
9. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev 2004;4:335-48 (Pubitemid 38579480)
10. Boulay A, Lane HA. The mammalian target of rapamycin kinase and tumor growth inhibition. Recent Results Cancer Res 2007;172:99-124
11. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81 (Pubitemid 46849157)
12. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56
13. Stein MN, Flaherty KT. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 2007;13:3765-70 (Pubitemid 47037579)
14. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24 (Pubitemid 46089672)
15. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90
16. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8
17. Rini BI. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. J Clin Oncol 2011;29:15S
18. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28:2144-50
19. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137-43
20. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109 (Pubitemid 39331023)
21. O'Dwyer PJ, Rosen M, Gallagher M, et al. Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma [abstract 3005]. ASCO Annual Meeting Proceedings, 41st Annual Meeting. J Clin Oncol 2005;23:193S
22. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72 (Pubitemid 46202316)
23. Strumberg D, Voliotis D, Moeller JG, et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 2002;40:580-1
24. Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 2006;42:548-56 (Pubitemid 43227936)
25. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12 (Pubitemid 46630627)
26. Choueiri TK, Brick AJ, McDermott S, et al. Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC) [abstract 593P]. Ann Oncol 2008;19(Suppl):viii191
27. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34 (Pubitemid 46089673)
28. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-18
29. Knox JJ, Figlin RA, Stadler WM, et al. The advanced renal cell carcinoma sorafenib (ARCSS) expanded access trial in North America: safety and efficacy [abstract 5011]. ASCO Annual Meeting Proceedings, 43rd Annual Meeting. J Clin Oncol 2007;25:237S
30. Bukowski RM, Stadler WM, McDermott DF, et al. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology 2010;78:340-7
31. Beck J, Bajetta E, Escudier B, et al. A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma [abstract 4506]. Eur J Cancer 2007;5(Suppl):300
32. Bellmunt J, Negrier S, Escudier B, et al. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol 2009;69:64-72
33. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-30
34. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-11 (Pubitemid 350296300)
35. Pfizer. Sutent (Sunitinib) Prescribing information. 2007. Available from: http://www.pfizer.com/pfizer/download/uspi-sutent.pdf [last accessed 1 January 2012]
36. Telli ML, Witteles RM, Fisher GA, et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008;19:1613-18
37. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 2008;99:448-54
38. Kelly RJ, Billemont B, Rixe O. Renal toxicity of targeted therapies. Target Oncol 2009;4:121-33
39. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008;26:3709-14
40. De Souza PL, Radulovic S, Beck J, et al. Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha [abstract 5116]. ASCO Annual Meeting Proceedings, 44th Annual Meeting. J Clin Oncol 2008;26:278S
41. Motzer RJ, Escudier B, Oudard S, et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter phase-III study [LBA 5026]. ASCO Annual Meeting Proceedings, 44th Annual Meeting. J Clin Oncol 2008;26
42. Massard C, Zonierek J, Gross-Goupil M, et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2010;21:1027-31
43. Choueiri TK, Duh MS, Clement J, et al. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int 2010;105:1247-54
44. Porta C, Paglino C, Imarisio I, et al. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer 2011;11:105
45. Sosman J, Puzanov I. Combination targeted therapy in advanced renal cell carcinoma. Cancer 2009;115(10 Suppl):2368-75
46. Sosman JA, Flaherty KT, Atkins MB, et al. Updated results of a phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer [abstract 5011]. ASCO Annual Meeting Proceedings, 44th Annual Meeting. J Clin Oncol 2008;26:252S
47. Rosenberg JE, Weinberg VK, Claros C, et al. Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma [abstract 5109]. ASCO Annual Meeting Proceedings, 44th Annual Meeting. J Clin Oncol 2008;26:276S
48. Giessinger S, Amato RJ, Jac J, et al. A phase I study with a daily regimen of the mTOR inhibitor RAD001 (everolimus) plus sorafenib for patients with metastatic renal cell cancer (mRCC) [abstract 14603]. ASCO Annual Meeting Proceedings, 44th Annual Meeting. J Clin Oncol 2008;26:635S
49. Patnaik A, Ricart A, Cooper J, et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib, a multi-targeted kinase inhibitor in combination with temsirolimus, an mTOR inhibitor in patients with advanced solid malignancies [abstract 3512]. ASCO Annual Meeting Proceedings, 43rd Annual Meeting. J Clin Oncol 2007;25:141S
50. Rini BI, Szczylik C, Tannir NM, et al. AMG 386 in combination with sorafenib in patients with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, phase II study. J Clin Oncol 2011;29(Suppl 7):abstract 309
51. Procopio G, Verzoni E, Bracarda S, et al. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer 2011;104:1256-61
52. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as firstor second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007;25:3288-95 (Pubitemid 47325614)
53. Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179:81-6.discussion 6 (Pubitemid 350216728)
54. Richter S, Pfister D, Thuer D, et al. Second line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib [abstract V684]. Onkologie 2009;31(Suppl):324
55. Mancuso AP, Donato De Paola E, Catalano A, et al. Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment. ASCO Annual Meeting Proceedings, 45th Annual Meeting. J Clin Oncol 2009;27:abstract e16027
56. Sepulveda J, Maroto P, Andres R, et al. Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): analysis for safety and activity on sunitinib progressive patients. ASCO Annual Meeting Proceedings, 44th Annual Meeting. J Clin Oncol 2008;26:abstract 16100
57. Zimmermann K, Schmittel A, Steiner U, et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009;76:350-4
58. Eichelberg C, Heuer R, Chun FK, et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008;54:1373-8
59. Dudek AZ, Zolnierek J, Dham A, et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009;115:61-7
60. Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009;182:29-34.discussion
61. Porta C, Procopio G, Sabbatini R, et al. Retrospective analysis of the sequential use of sorafenib and sunitinib in patients with advanced renal cell carcinoma (RCC). Eur Urol 2009;8(Suppl 4):abstract 252
62. Buchler T, Klapka R, Melichar B, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma - data from the Czech registry. Ann Oncol [Epub ahead of print 2 May 2011; doi: 10.1093/annonc/mdr065]
63. Busch J, Seidel C, Kempkensteffen C, et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol 2011;60:1163-70
64. Herrmann E, Marschner N, Grimm MO, et al. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol 2011;29:361-6
65. Heuer R, Becker A, Dahlem R, et al. Overall Survival (OS) nach sequentieller Therapie (ST) mit Sorafenib (So), Sunitinib (Su) und mTOR inhibitoren beim metastasierten nierenzellkarzinom [abstract CD 63]. Kongress der Deutschen Gesellschaft fur Urologie e.V. 2011
66. Shepard DR, Rini RI, Garcia JA, et al. A multicenter prospective trial of sorafenib in patients with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab [abstract 5123]. ASCO Annual Meeting Proceedings, 44th Annual Meeting. J Clin Oncol 2008;26:280S
67. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31